In an attempt to improve the dismal prognosis of adults with recurrent medulloblastoma, six patients were treated with aggressive salvage therapy including highdose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). At relapse, all patients underwent surgical debulking followed by HDCT/ASCT and then radiotherapy when possible. The treatment plan included two cycles of HDCT/ASCT; first with cyclophosphamide, etoposide and carboplatin (CECb) and then 2 months later with cyclophosphamide and thiotepa (CT). Three of the six patients received the planned therapy. One patient experienced severe toxicity requiring life-sustaining therapy. This patient developed multi-organ dysfunction including multiple enhancing lesions in both cerebral hemispheres that slowly resolved over several months. Two other patients did not mobilize sufficient stem cells for two ASCT procedures. They received one ASCT conditioned with cyclophosphamide, thiotepa and carboplatin (CTCb). Three of six patients had a complete response (CR); the other three had a partial response (PR). Following the first ASCT, median duration of response was 13.5 months (range 9-29 months) and median survival was 21.5 months (range 12-42 months). There was no treatment-related mortality. We conclude that HDCT/ASCT with CECb-CT or CTCb is active against recurrent medulloblastoma in adults and may be associated with prolonged remissions. Multiple enhancing cerebral lesions on brain MRI early post-HDCT/ASCT may be a consequence of the treatment rather than metastatic disease.
The prognosis of adults with recurrent medulloblastoma remains poor, with median survival rates reported to be as low as 5 months. 1 Currently, there is no generally acceptable therapy for tumor recurrences. The most active chemotherapeutic agents include cisplatin or carboplatin, [2] [3] [4] lowdose oral etoposide, 5 PCV (procarbazine, CCNU, vincristine), 6 MOPP (nitrogen mustard, vincristine, procarbazine, prednisone), 7 and intraventricular and intrathecal therapy with Ara-C, methotrexate and thiotepa. 8 Despite reasonably high response rates of 40-75% with these agents, no long-term disease-free survival has been reported. [1] [2] [3] [4] [5] [6] [7] [8] [9] Given that these agents are amenable to substantial dose-escalation, evaluation of high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) has been suggested. 9 Promising results with HDCT/ASCT prompted us to use this form of therapy for young adults with recurrent medulloblastoma, who were otherwise healthy and had no possibility of cure with conventional dose therapy. [10] [11] [12] [13] [14] [15] Here, we report the outcomes of six adults who underwent HDCT (cyclophosphamide, carboplatin, thiotepa, etoposide) with ASCT for medulloblastoma relapse. Table 1 lists the clinical profile of patients 1-6. Between March 1995 and November 1999, these patients were treated with this regimen at the Tom Baker Cancer Centre in Calgary, Alberta. This report includes follow-up of these patients as of May 2001. The patient sample included five males and one female with a median age of 25 years (range: 8-33 years) at the time of initial diagnosis. All patients were initially treated with surgery and radiation Ϯ pre-radiation chemotherapy (three courses of vincristine and carboplatin). All patients had histologically documented recurrent medulloblastoma. The median age at relapse was 29.5 years (range: 21-35 years). The median time to relapse from initial diagnosis was 40 months (range: 19-204 months) . Tumor staging at the time of relapse was done using the Chang system. M0 indicates no evidence of metastatic disease, M1 is classified as positive CSF cytology, M2 as gross nodular seeding of cerebral or cerebellar subar- achanoid space or in the third or lateral ventricles, M3 as gross nodular seeding of the spinal subarachnoid space, and M4 as extraneuroaxial metastases. At the time of relapse, the M stage was M0 in two patients, M1 in one patient, M2 in two patients, M3 in one patient and M4 in no patient. Histologically, three patients had the classic form of medulloblastoma, whereas the other three had the desmoplastic variant.
Patients and methods

Patients
After relapse, three of the six patients underwent surgical resection, two had a combination of surgery and chemotherapy, and one patient had chemotherapy alone. None of the six patients received radiation therapy. Despite these efforts, all patients had symptomatic disease at the time of protocol. The median time from radiographic relapse to the first cycle of HDCT/ASCT was 7 months (range: 2-22 months). All patients had a Karnofsky score of 60% or greater before the administration of the protocol.
Protocol
The original protocol consisted of two cycles of high-dose chemotherapy as follows. Leukapheresis was performed in all patients after chemotherapy and G-CSF administration, leading to the collection and cryopreservation of stem cells. On days Ϫ6, Ϫ5, and Ϫ4 patients received carboplatin (600 mg/m 2 over 1 h), etoposide (600 mg/m 2 over 3 h) and cyclophosphamide (50 mg/kg over 1 h). Approximately 96 h after completion of chemotherapy, the cryopreserved stem cells were reinfused. On day +1, granulocyte colonystimulating factor (G-CSF) was administered at a dose of 300 g (if less than 70 kg) or 480 g (if over 70 kg) via the subcutaneous route once daily, until the neutrophils engrafted.
For the patients who had initially mobilized sufficient stem cells and established hematopoietic recovery, the second cycle of chemotherapy was administered. On days Ϫ7, Ϫ6, Ϫ5, thiotepa (250 mg/m 2 over 24 h) and cyclophosphamide (2 g/m 2 over 24 h) were administered. About 120 h later, the remaining stem cells from the initial harvest were reinfused. Once again, G-CSF was administered as per the first cycle.
Response assessment
Patients were assessed by the use of brain and spine MRI after the first and second cycles of HDCT/ASCT, along with CSF cytology if there were prior evidence of metastasis. Standard radiographic criteria were used to determine response. Complete response (CR) was defined as complete resolution of all lesions and no clinical progression. Partial response (PR) was defined as a >50% reduction in the product of the maximum perpendicular diameters of all lesions and no clinical progression. Stable disease (SD) was defined as <50% reduction and <25% increase in size with no clinical progression, and progressive disease (PD) was defined as >25% increase in size. The patients' Karnofsky scores at the time of relapse and shortly (<30 days) after completing the course of chemotherapy were also recorded.
Results
Protocol delivery
Three out of six patients (Nos 2, 3 and 5) received the planned two cycles of HDCT/ASCT with CECb followed by CT. Two patients (Nos 4 and 6) did not mobilize sufficient stem cells for two ASCT procedures (only 1.3 and 3.2 ϫ 10 6 CD34 cells/kg collected). Both these patients had received craniospinal radiotherapy in the past. Consequently, these two patients received only one cycle of HDCT using cyclophosphamide, carboplatin and thiotepa (same doses as above). One patient (No. 1) experienced severe toxicity from CECb/ASCT and declined the second transplant. For all six patients, the CD34 + cell dose ranged from 1.3 to 7.5 ϫ 10 6 cells/kg for the first cycle of HDCT/ASCT. The CD34 + cell dose for the three patients who received the second ASCT ranged from 3.6 to 15 ϫ 10 6 CD34 cells/kg. , he received a relatively high carboplatin dose of 1800 mg i.v. daily for 3 days; equivalent to a total dose of 2347 mg/m 2 . On the evening of the third chemotherapy day, well before he became neutropenic, he developed fever of 39.4°C and experienced persistent fever until day +7 post-transplant. He developed progressive azotemia over the first few days following HDCT with a peak creatinine of 244 mol/l on day +2 post-transplant. On day +3 he became delirious and by day +5 he was very drowsy, noncommunicative, and bedridden. He did not develop focal neurological signs. A lumbar puncture revealed normal CSF cell count, protein, glucose, culture/sensitivity, viral studies and cytology. Neither a brain CT scan on day +3 nor a brain MRI scan on day +4 revealed any evidence of abscess, hemorrhage, stroke or tumor. On day +4 he developed intermittent atrial fibrillation and cardiomegaly on chest X-ray. He was diagnosed with a systemic inflammatory syndrome and was treated with high-dose corticosteroid therapy from day +4 to +9, initially with dexamethasone 20 mg i.v. followed by solumedrol 60 mg twice a day. His fever, azotemia and delirium improved fairly rapidly over the next few days. His steroids were tapered over 3 days and then discontinued on day +13. On day +16 his fever returned, again with no focus of infection and negative cultures. He was started on prednisone 50 mg daily on day +18 and defervesed once again. The patient was discharged on day +24 post-ASCT with ataxia and generalized weakness requiring a walking aid. These symptoms resolved over the ensuing month after discharge, despite being tapered off steroids. Six weeks after discharge, this patient was noted for the first time to have multiple enhancing foci with surrounding edema in the cerebral hemispheres on a follow-up MRI (Figure 1 ). On T1-weighted images there was a grouping of lesions in the left corona radiata, two small enhancing lesions in the right superior frontal region, single lesions in the right inferior frontal, right external capsule, and left medial temporal lobe. A small lesion was seen along the lateral aspect of the right middle cerebellar peduncle. The T2-weighted images demonstrated significant edema surrounding the larger lesions. There was no particular pattern to the lesions such as periventricular or perivascular. These abnormalitites were initially thought to represent metastatic tumors. The lesions gradually decreased in size over several months until they virtually disappeared some 15 months later. There were no abnormalities in renal function, liver enzymes, serum electrolytes, nor similar MRI findings in any other patient after the HDCT/ASCT. Table 2 summarizes the response data from the six patients. All patients eventually relapsed post-ASCT. The median progression-free interval from the first ASCT was 13.5 months and from the time of radiographic relapse was 23 months (range: 15-41 months). For all patients, the median total survival time from the time of the first cycle of HDCT/ASCT was 21.5 months and from the time of radiographic relapse was 26.5 months (range: 21-54 months).
Response and survival
Discussion
Despite advances in the treatment of medulloblastoma at initial diagnosis, the prognosis is dismal for patients that relapse. Recurrent disease treated with surgery, radiation or conventional chemotherapy has been shown to have a median survival time of 5 months with no long-term survivors. 1 We present a small case series of six adults who underwent HDCT with ASCT for medulloblastoma relapse.
The rationale for using HDCT with stem cell rescue for medulloblastoma is based on the fact that brain tumors are sensitive to chemotherapeutic agents that have hematopoietic dose-limiting toxicity. 16, 17 By employing the use of a stem cell transplant to increase the tolerable dose of chemotherapy, the potential dose-dependent sensitivity of medulloblastoma can be fully exploited. 10, 18 The rationale for specifically using cyclophosphamide, carboplatin, etoposide and thiotepa in our regimen stems from their efficacy demonstrated in previous studies. 4, [11] [12] [13] Thiotepa in particular is a polyfunctional alkylating agent that has shown significant activity against human medulloblastoma cell lines both in vitro and in xenograft models. 18, 19 Both thiotepa and its active metabolite tepa cross the blood-brain barrier efficiently, making it a very promising agent in the setting of CNS tumors. 14, [20] [21] [22] One case report of two patients has shown that high-dose chemotherapy consisting of busulfan and thiotepa followed by infusion of autologous hematopoietic stem cells produced disease-free survival times of 20 and 27 months after bone marrow relapse of medulloblastoma. 15 High-dose carboplatin, thiotepa and etoposide with autologous stem-cell rescue have also shown some activity against recurrent medulloblastoma.
11
High-dose chemotherapy is still thought to be an experimental procedure that has yet to show a clear advantage over conventional chemotherapy in adult recurrent medulloblastoma.
Our study parallels the report by Dunkel et al 11 in 1998 that uses a similar regimen. We employed the use of two cycles followed by stem cell rescue with a total etoposide dose of 1800 mg/m 2 and a total thiotepa dose of 750 mg/m 2 . In contrast, Dunkel et al administered a total etoposide dose of 750 mg/m 2 and a total thiotepa dose of 900 mg/m 2 . Our study is also unique because we treated an older patient population (median age at time of protocol of 31 years) as compared to previous studies.
Our results support the findings of Dunkel et al that the use of high-dose chemotherapy in conjunction with stem cell rescue is associated with a favorable response with a potential for long-term survival in some patients. Despite their advanced age, all of our patients responded to treatment with a minimum 50% reduction in tumor size. This is an improvement in comparison to response rates ranging from 40 to 75% with conventional chemotherapy. [2] [3] [4] [5] [6] [7] [8] [9] Among patients who had a second recurrence, we report an even longer median time to relapse post high-dose chemotherapy as compared to Dunkel et al (13.5 vs 7 months), with two patients surviving with stable disease. It is interesting to note that patients with metastatic disease (>M0) had a comparable median time to relapse as compared to those with no metastatic disease (16 vs 13 months). This shows that this regimen has activity against both aggressive and non-aggressive forms of the disease. Both the classic form of medulloblastoma and the desmoplastic variant responded equally with a median time to relapse of 12 and 14 months, respectively.
One patient developed severe multi-organ dysfunction early post-CECb/ASCT. A follow-up brain MRI (Figure 1 ) done 6 weeks later showed peculiar enhancing lesions that were initially thought to be metastases or toxicity from CECb. While peripheral neuropathy has been reported to occur in as many as 6% of patients receiving carboplatin, CNS toxicity with enhancing foci has not been documented. 23 The gradual resolution of these lesions over several months was as mysterious as their initial appearance. He did not receive long-term antibiotics of any sort post-ASCT, not even bactrim for PCP prophylaxis. It seems very unlikely to us that his neurological complications could have been due to a severe infection that spontaneously resolved without any specific therapy, particularly in the setting of immunosuppression post-ASCT. We feel that a more likely explanation was that the neurotoxicity was part of the multisystem regimen-related toxicity experienced by the patient. Specifically, we feel the carboplatin was the likely culprit because of its known association with peripheral neurotoxicity, and because our patient received a particularly high dose of carboplatin relative to the other patients we have treated. Nevertheless, we cannot prove our opinion because the lesions were never biopsied. The case does illustrate, however, the important fact that enhancing lesions seen on brain MRI scans early post-ASCT may not be due to metastatic cancer.
The limitations of this study include inconsistencies in regimen administration. One patient did not receive thiotepa at all and two did not receive any etoposide. However, all patients received at least one of the above. In addition, four patients received adjuvant radiation therapy and one patient had a microsurgical resection after the administration of high-dose chemotherapy with stem cell rescue. However, the patient who did not receive any adjuvant treatment had a comparable median time to relapse as the others (13 vs 14 months). Another limitation is that this is a small retrospective study that does not allow us to determine which patient population would benefit the most from this type of treatment.
Although HDCT/ASCT does not cure relapsed medulloblastoma in adults, it does result in high response rates and possibly some improvement in survival. Encouraging results from a pilot study of high-dose thiotepa and etoposide with ASCT in children and young adults with recurrent high-grade gliomas has merited the evaluation of such agents as part of first-line treatment in newly diagnosed patients with these tumors. 13 Similarly, since HDCT/ASCT is very active even in the setting of recurrent medulloblastoma, perhaps the efficacy and tolerability would be enhanced if this regimen were to be employed as part of front-line treatment. The concern in this regard would be subjecting patients to excess toxicity who might have otherwise been cured by less intensive treatment. However, long-term follow-up suggests frequent late relapses and overall low cure rates for most patients with medulloblastoma who receive conventional treatment. 1, 9 
